Comparative studies on the mechanisms of action of four polysaccharides on arterial restenosis
Related Experiment Video
Updated: Jun 24, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Jean-François Deux1, Anne Meddahi-Pellé, Françoise Bree
1INSERM, U 698, Cardiovascular Bio-engineering, X Bichat Hospital, Bât INSERM 13 46 rue H. Huchard, 75877 Paris, Cedex 18, France.
Insights
Low-molecular-weight fucoidan effectively reduces in-stent restenosis after angioplasty. Its anti-restenotic effects depend on pharmacokinetic properties and vascular wall binding, not just smooth muscle cell antiproliferative activity.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Biomaterials Science
Background:
- Percutaneous coronary interventions are key for coronary artery disease management.
- In-stent restenosis, a lumen reduction post-procedure, impairs intervention efficacy.
- Fucoidan, a vegetal polysaccharide, shows promise in reducing restenosis.
Purpose of the Study:
- To elucidate the in vivo anti-restenotic mechanisms of fucoidan fractions.
- To compare fucoidan with heparin and dextran regarding anti-restenotic effects.
- To identify key factors influencing fucoidan's efficacy in preventing restenosis.
Main Methods:
- Characterization and fractionation of natural fucoidan.
- In vitro studies on vascular smooth muscle cell proliferation.
- In vivo pharmacokinetic analysis and local delivery of fluorescently-labeled polysaccharides in rabbit iliac arteries post-angioplasty.
Main Results:
- Well-characterized fucoidan fractions are essential for reliable in vitro and in vivo studies.
- In vitro antiproliferative activity of sulphated polysaccharides does not reliably predict in vivo restenosis reduction.
- Pharmacokinetic parameters and binding of low-molecular-weight fucoidan to injured vascular walls are critical factors.
Conclusions:
- Low-molecular-weight fucoidan demonstrates significant in-stent restenosis reduction in vivo.
- Fucoidan's anti-restenotic efficacy is influenced by its pharmacokinetic profile and localized binding to the vascular wall.
- Standardized fucoidan fractions and understanding their in vivo behavior are crucial for therapeutic development.
Abstract:
Percutaneous coronary interventions play a major role in the management of patients affected by coronary artery diseases. However, their efficiency is impaired by restenosis, defined as a reduction of the vessel lumen, occurring a few months after the procedure. A low-molecular-weight fraction of fucoidan, a vegetal heparin-like sulphated polysaccharide, was recently shown to greatly reduce in-stent restenosis after angioplasty in rabbits. To better understand the in vivo anti-restenotic effects of this polymer, we used fractions of fucoidan and compared to heparin and dextran of different sizes. We carried out in vitro growth inhibition experiments on vascular smooth muscle cells, performed an in vivo pharmacokinetic study, and locally delivered fluorescently-labeled polysaccharides in rabbit iliac arteries after angioplasty with a non-occlusive catheter. The results indicated that (i) preparation of well-characterized fractions from natural fucoidan is compulsory for in vitro and in vivo studies, (ii) antiproliferative activity of sulphated polysaccharides on cultured smooth muscle cells is not a major predictive factor for the reduction of restenosis in vivo and (iii) pharmacokinetic parameters and binding of low-molecular-weight fucoidan on angioplasty-induced injured vascular walls are important local and general factors controlling its mechanisms of action.
